Table 3. The efficacy (overall survival and progression-free survival) of eight drugs in chemotherapy of glioblastoma followed by surgery and radiotherapy according to the network meta-analysis using hazard ratio (HR) and corresponding 95% credible intervals (CrIs).

Endpoints	OS
PFS	Placebo	1.47 (1.25, 1.73)	1.23 (0.98, 1.55)	1.67 (1.34, 2.08)	1.47 (0.90, 2.39)	1.63 (1.27, 2.10)	2.83 (1.29, 6.21)	1.30 (0.94, 1.79)	1.23 (0.96, 1.58)
	0.63 (0.54, 0.73)	TMZ	0.84 (0.64, 1.11)	1.14 (0.98, 1.32)	1.00 (0.60, 1.67)	1.11 (0.91, 1.35)	1.92 (0.89, 4.15)	0.88 (0.62, 1.26)	0.84 (0.62, 1.13)
	0.65 (0.53, 0.80)	1.03 (0.80, 1.34)	PCV	1.35 (0.99, 1.86)	1.19 (0.70, 2.04)	1.32 (0.94, 1.85)	2.29 (1.01, 5.20)	1.05 (0.71, 1.56)	1.00 (0.90, 1.11)
	0.40 (0.32, 0.50)	0.64 (0.55, 0.75)	0.62 (0.46, 0.84)	BEV+TMZ	0.88 (0.52, 1.50)	0.97 (0.76, 1.24)	1.69 (0.77, 3.71)	0.78 (0.53, 1.14)	0.74 (0.53, 1.03)
	0.75 (0.49, 1.15)	1.19 (0.75, 1.88)	1.15 (0.71, 1.86)	1.86 (1.15, 3.02)	Nimotuzumab	1.11 (0.64, 1.92)	1.92 (0.76, 4.85)	0.88 (0.49, 1.58)	0.84 (0.49, 1.45)
	0.57 (0.45, 0.71)	0.90 (0.76, 1.06)	0.87 (0.64, 1.18)	1.41 (1.12, 1.77)	0.76 (0.47, 1.23)	Cilengitide+TMZ	1.74 (0.78, 3.84)	0.80 (0.53, 1.20)	0.76 (0.53, 1.08)
	0.56 (0.30, 1.05)	0.89 (0.48, 1.63)	0.86 (0.44, 1.66)	1.39 (0.74, 2.61)	0.75 (0.35, 1.60)	0.99 (0.53, 1.85)	TMZ+ACNU+CDDP	0.46 (0.20, 1.07)	0.44 (0.19, 1.00)
	0.75 (0.57, 0.98)	1.19 (0.87, 1.62)	1.15 (0.81, 1.62)	1.86 (1.31, 2.64)	1.00 (0.60, 1.67)	1.32 (0.93, 1.88)	1.34 (0.68, 2.65)	DBD+BCNU	0.95 (0.63, 1.42)
	0.65 (0.52, 0.82)	1.03 (0.78, 1.36)	1.00 (0.91, 1.10)	1.62 (1.18, 2.23)	0.87 (0.53, 1.42)	1.15 (0.83, 1.59)	1.17 (0.60, 2.27)	0.87 (0.61, 1.25)	DMFO+PCV